Diabetes Prevention Program Genetics (DPPG)

TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.

J. Florez, K. Jablonski, N. Bayley, et al.. (2006). The New England journal of medicine. Cited 821 times. https://doi.org/10.1056/NEJMOA062418

Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program

K. Jablonski, J. Mcateer, P. D. de Bakker, et al.. (2010). Diabetes. Cited 259 times. https://doi.org/10.2337/db10-0543

Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program

M. Hivert, K. Jablonski, L. Perreault, et al.. (2011). Diabetes. Cited 176 times. https://doi.org/10.2337/db10-1119

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.

J. Florez, K. Jablonski, Maria W Sun, et al.. (2007). The Journal of clinical endocrinology and metabolism. Cited 139 times. https://doi.org/10.1210/JC.2006-2275

Type 2 Diabetes–Associated Missense Polymorphisms KCNJ11 E23K and ABCC8 A1369S Influence Progression to Diabetes and Response to Interventions in the Diabetes Prevention Program

J. Florez, K. Jablonski, S. Kahn, et al.. (2007). Diabetes. Cited 124 times. https://doi.org/10.2337/db06-0966

Genetic Predictors of Weight Loss and Weight Regain After Intensive Lifestyle Modification, Metformin Treatment, or Standard Care in the Diabetes Prevention Program

L. Delahanty, Q. Pan, K. Jablonski, et al.. (2012). Diabetes Care. Cited 117 times. https://doi.org/10.2337/dc11-1328

Extension of Type 2 Diabetes Genome-Wide Association Scan Results in the Diabetes Prevention Program

Allan F. Moore, K. Jablonski, J. Mcateer, et al.. (2008). Diabetes. Cited 105 times. https://doi.org/10.2337/db08-0284

The Pro12Ala variant at the peroxisome proliferator-activated receptor γ gene and change in obesity-related traits in the Diabetes Prevention Program

P.W Franks, P.W Franks, P.W Franks, et al.. (2007). Diabetologia. Cited 75 times. https://doi.org/10.1007/s00125-007-0826-6

The C Allele of ATM rs11212617 Does Not Associate With Metformin Response in the Diabetes Prevention Program

J. Florez, K. Jablonski, Andrew W. Taylor, et al.. (2012). Diabetes Care. Cited 75 times. https://doi.org/10.2337/dc11-2301

Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program

J. Florez, K. Jablonski, J. Mcateer, et al.. (2008). Diabetologia. Cited 72 times. https://doi.org/10.1007/s00125-007-0891-x

Assessing gene–treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program

P. Franks, P. Franks, K. Jablonski, et al.. (2008). Diabetologia. Cited 66 times. https://doi.org/10.1007/s00125-008-1158-x

The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program.

Allan F. Moore, K. Jablonski, Clinton C. Mason, et al.. (2009). The Journal of clinical endocrinology and metabolism. Cited 56 times. https://doi.org/10.1210/jc.2008-1583

Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism.

T. Pollin, K. Jablonski, J. Mcateer, et al.. (2011). The Journal of clinical endocrinology and metabolism. Cited 43 times. https://doi.org/10.1210/jc.2010-2324

Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program

T. Pollin, T. Isakova, K. Jablonski, et al.. (2012). PLoS Genetics. Cited 34 times. https://doi.org/10.1371/journal.pgen.1002895

Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program

T. Pollin, T. Isakova, K. Jablonski, et al.. (2012). PLoS Genetics. Cited 34 times. https://doi.org/10.1371/journal.pgen.1002895

Common variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/2), adiponectin concentrations, and diabetes incidence in the Diabetes Prevention Program

K. Mather, C. Christophi, K. Jablonski, et al.. (2012). Diabetic Medicine. Cited 33 times. https://doi.org/10.1111/j.1464-5491.2012.03662.x

TCF7L2 Polymorphism, Weight Loss and Proinsulin∶Insulin Ratio in the Diabetes Prevention Program

J. McCaffery, K. Jablonski, P. Franks, et al.. (2011). PLoS ONE. Cited 28 times. https://doi.org/10.1371/journal.pone.0021518

Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program

Amit R. Majithia, Amit R. Majithia, K. Jablonski, et al.. (2011). Diabetologia. Cited 22 times. https://doi.org/10.1007/s00125-011-2234-1